The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma

被引：241

作者：

Berry, Teeara ^{[1
,2
]}

Luther, William ^{[4
]}

Bhatnagar, Namrata ^{[4
]}

Jamin, Yann ^{[3
]}

Poon, Evon ^{[1
,2
]}

Sanda, Takaomi ^{[4
]}

Pei, Desheng ^{[4
]}

Sharma, Bandana ^{[4
]}

Vetharoy, Winston R. ^{[1
,2
]}

Hallsworth, Albert ^{[1
,2
]}

Ahmad, Zai ^{[1
,2
]}

Barker, Karen ^{[1
,2
]}

Moreau, Lisa ^{[4
]}

Webber, Hannah ^{[1
,2
]}

Wang, Wenchao ^{[4
]}

Liu, Qingsong ^{[5
]}

Perez-Atayde, Antonio ^{[7
]}

Rodig, Scott ^{[6
]}

Cheung, Nai-Kong ^{[8
]}

Raynaud, Florence ^{[1
,2
]}

Hallberg, Bengt ^{[9
]}

Robinson, Simon P. ^{[3
]}

Gray, Nathanael S. ^{[5
]}

Pearson, Andrew D. J. ^{[1
,2
,10
]}

Eccles, Suzanne A. ^{[1
,2
]}

Chesler, Louis ^{[1
,2
,10
]}

George, Rani E. ^{[4
]}

机构：

[1] Inst Canc Res, Div Clin Studies, Surrey SM2 5NG, England

[2] Inst Canc Res, Div Canc Therapeut, Surrey SM2 5NG, England

[3] Inst Canc Res, Div Radiotherapy & Imaging, Surrey SM2 5NG, England

[4] Harvard Univ, Sch Med, Dana Farber Canc Inst & Childrens Hosp Boston, Dept Pediat Hematol & Oncol, Boston, MA 02115 USA

[5] Harvard Univ, Sch Med, Dana Farber Canc Inst & Biol Chem & Mol Pharmacol, Dept Canc Biol, Boston, MA 02115 USA

[6] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA

[7] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA

[8] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA

[9] Umea Univ, Dept Mol Biol, Umea, Sweden

[10] Royal Marsden NHS Trust, Children & Young Peoples Unit, Surrey SM2 5PT, England

来源：

CANCER CELL | 2012年 / 22卷 / 01期

基金：

英国惠康基金; 英国医学研究理事会; 英国工程与自然科学研究理事会; 美国国家卫生研究院;

关键词：

ANAPLASTIC LYMPHOMA KINASE; N-MYC; ALK KINASE; C-MYC; ACTIVATING MUTATIONS; EXPRESSION; PHOSPHORYLATION; PROGRESSION; INHIBITION; RESISTANCE;

D O I：

10.1016/j.ccr.2012.06.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The ALK(F1174L) mutation is associated with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma. In this study, we generated a mouse model overexpressing ALK(F1174L) in the neural crest. Compared to ALKF1174L and MYCN alone, co-expression of these two oncogenes led to the development of neuroblastomas with earlier onset, higher penetrance, and enhanced lethality. ALK(F1174L)/MYCN tumors exhibited increased MYCN dosage due to ALK(F1174L)-induced activation of the PI3K/AKT/mTOR and MAPK pathways, coupled with suppression of MYCN pro-apoptotic effects. Combined treatment with the ATP-competitive mTOR inhibitor Torin2 overcame the resistance of ALK(F1174L)/MYCN tumors to crizotinib. Our findings demonstrate a pathogenic role for ALK(F1174L) in neuroblastomas overexpressing MYCN and suggest a strategy for improving targeted therapy for ALK-positive neuroblastoma.

引用

页码：117 / 130

页数：14

共 44 条

[1] Conditional transgenic models define how MYC initiates and maintains tumorigenesis
Arvanitis, Constadina
Felsher, Dean W.
[J]. SEMINARS IN CANCER BIOLOGY, 2006, 16 (04) : 313 - 317
[2] BANERJEE SA, 1992, J NEUROSCI, V12, P4460
[3] Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Bresler, Scott C.
Wood, Andrew C.
Haglund, Elizabeth A.
Courtright, Joshua
Belcastro, Lili T.
Plegaria, Jefferson S.
Cole, Kristina
Toporovskaya, Yana
Zhao, Huaqing
Carpenter, Erica L.
Christensen, James G.
Maris, John M.
Lemmon, Mark A.
Mosse, Yael P.
[J]. SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (108)
[4] AMPLIFICATION OF N-MYC IN UNTREATED HUMAN NEUROBLASTOMAS CORRELATES WITH ADVANCED DISEASE STAGE
BRODEUR, GM
SEEGER, RC
SCHWAB, M
VARMUS, HE
BISHOP, JM
[J]. SCIENCE, 1984, 224 (4653) : 1121 - 1124
[5] Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, James E.
D'Adamo, David R.
Hornick, Jason L.
Dal Cin, Paola
Antonescu, Cristina R.
Jhanwar, Suresh C.
Ladanyi, Marc
Capelletti, Marzia
Rodig, Scott J.
Ramaiya, Nikhil
Kwak, Eunice L.
Clark, Jeffrey W.
Wilner, Keith D.
Christensen, James G.
Jaenne, Pasi A.
Maki, Robert G.
Demetri, George D.
Shapiro, Geoffrey I.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) : 1727 - 1733
[6] Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma
Chanthery, Yvan H.
Gustafson, W. Clay
Itsara, Melissa
Persson, Anders
Hackett, Christopher S.
Grimmer, Matt
Charron, Elise
Yakovenko, Slava
Kim, Grace
Matthay, Katherine K.
Weiss, William A.
[J]. SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (115)
[7] Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Yuyan
Takita, Junko
Choi, Young Lim
Kato, Motohiro
Ohira, Miki
Sanada, Masashi
Wang, Lili
Soda, Manabu
Kikuchi, Akira
Igarashi, Takashi
Nakagawara, Akira
Hayashi, Yasuhide
Mano, Hiroyuki
Ogawa, Seishi
[J]. NATURE, 2008, 455 (7215) : 971 - U56
[8] Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma
Chesler, Louis
Schlieve, Chris
Goldenberg, David D.
Kenney, Anna
Kim, Grace
McMillan, Alex
Matthay, Katherine K.
Rowitch, David
Weiss, William A.
[J]. CANCER RESEARCH, 2006, 66 (16) : 8139 - 8146
[9] The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, Roberto
Voena, Claudia
Ambrogio, Chiara
Piva, Roberto
Inghirami, Giorgio
[J]. NATURE REVIEWS CANCER, 2008, 8 (01) : 11 - 23
[10] Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
Christensen, James G.
Zou, Helen Y.
Arango, Maria E.
Li, Qiuhua
Lee, Joseph H.
McDonnell, Scott R.
Yamazaki, Shinji
Alton, Gordon R.
Mroczkowski, Barbara
Los, Gerrit
[J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3314 - 3322

← 1 2 3 4 5 →